期刊文献+

阿尔茨海默病血浆生物标志物研究进展 被引量:1

下载PDF
导出
摘要 阿尔茨海默病(AD)是最常见的痴呆性疾病,研究者一直在寻找用于该病确定诊断的血浆或血清生物标志物。该文对与AD主要病理过程如淀粉样蛋白斑形成、炎症反应、氧化应激、脂质代谢和血管病变等相关的一些血浆生物标志物的研究进展作一综述。
出处 《国际检验医学杂志》 CAS 2006年第3期267-269,共3页 International Journal of Laboratory Medicine
  • 相关文献

参考文献19

  • 1Solfrizzi V,Panza F,D'Introno A,et al.Lipoprotein(a),apolipoprotein E genotype,and risk of Alzheimer's disease.J Neurol Neurosurg Psychiatry,2002,72(6):732-736.
  • 2Fukumoto H,Tennis M,Locascio JJ,et al.Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.Arch Neurol,2003,60(7):958-964.
  • 3Mayeux R,Honig LS,Tang MX,et al.Plasma A[beta]40 and A[beta]42 and Alzheimer's disease:relation to age,mortality,and risk.Neurology,2003,61(9):1185-1190.
  • 4Hock C,Konietzko U,Streffer JR,et al.Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.Neuron,2003,38(4):547-554.
  • 5Orgogozo JM,Gilman S,Dartigues JF,et al.Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.Neurology,2003,61(1):46-54.
  • 6Padovani A,Borroni B,Colciaghi F,et al.Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease.Arch Neurol,2002,59(1):71-75.
  • 7Baskin F,Rosenberg RN,Fang X,et al.Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients.Neurology,2003,60(12):2006-2007.
  • 8Borroni B,Colciaghi F,Lenzi GL,et al.High cholesterol affects platelet APP processing in controls and in AD patients.Neurobiol Aging,2003,24(5):631-636.
  • 9Dufouil C,Richard F,Fiévet N,et al.APOE genotype,cholesterol level,lipid-lowering treatment,and dementia.Neurology,2005,64(9):1531-1538.
  • 10Tan ZS,Seshadri S,Beiser A,et al.Plasma total cholesterol level as a risk factor for Alzheimer disease:the Framingham Study.Arch Intern Med,2003,163(9):1053-1057.

同被引文献21

  • 1许琴华,曹非.Alzheimer病生物标志物表达的研究进展[J].现代生物医学进展,2006,6(9):102-104. 被引量:4
  • 2Blennow K. Cerebrospinal Fluid Protein Biomarkers for Alzhei- mer's Disease[J]. NeuroRx, 2004,1 (2) : 213-225.
  • 3Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF [J]. Neurology, 1999,52(8) : 1555-1562.
  • 4Mattsson N,Zetterberg H, Hansson O,et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impair- ment[J]. Journal of the American Medical Association, 2009,302 (4) :385-393.
  • 5Sjogren M,Vanderstichele H,Agren H,et al. Tau and Abeta42 in eerebrospinal fluid from healthy adults 21-93 years of age: estab- lishment of reference values[J]. Clin Chem, 2001,47 ( 10 ): 1776- 1781.
  • 6Mattsson N,Zetterberg H,Hansson O,et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impair ment[J]. Journal of the American Medical Association, 2009,302 (4) :385 -393.
  • 7Hansson O, Zetterberg H, Buchhave P, et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment;a follow-up study[J]. Lancet Neurolo- gy,2006,5(3) :228-234.
  • 8Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/beta- amyloid(42) ratio as a prediction of cognitive decline in nonde- mented older adults[J]. Arch Neurol, 2007,64 (3) : 343-349.
  • 9Bouwman FH, Vander-Flier WM, Schoonenboom NS, et al. Use- fulness of longitudinal measurements of beta-amyloid 1-42 in cere- brospinal fluid of patients with various cognitive and neurologic disorders[J]. Clin Chem,2006,52(8) : 1604-1606.
  • 10Mulugeta E,Londos E,Ballard C, et al. CSF amyloid beta38 as a novel diagnostic marker for dementia with Lewy bodies[J]. Neu- rol Neurosurg Psyehiatr,2010,82(2) :160-164.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部